In a promotional video for the Sapien Center, a private health club in East Austin, shirtless men vault over picnic tables and lasers strobe to the beat of Diplo-esque techno. A woman swings from ...

Edwards Lifesciences Corp.’s Sapien 3 platform has been approved for a new indication. The Food and Drug Administration recently cleared the line of catheter-based heart valves, which includes Sapien ...

Get Instant Summarized Text (Gist) The FDA has approved the SAPIEN 3 TAVR platform for patients with severe asymptomatic aortic stenosis. In a median 3.8-year follow-up, TAVR reduced the combined ...

MONDAY, May 5, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved the SAPIEN 3 platform, a transcatheter aortic valve replacement (TAVR) therapy, for patients with severe ...

FDA Approves SAPIEN 3 Platform for Asymptomatic Severe Aortic Stenosis By Lori Solomon HealthDay ReporterMONDAY, May 5, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved ...

IRVINE, Calif., April 14, 2025--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the ...

Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of patients with symptomatic ...

Edwards Lifesciences Corp. today announced that it received CE Mark approval, the European equivalent of the Food and Drug Administration, for its Sapien M3 mitral replacement system. The device ...

As legal battles continue between the manufacturers, the COMPARE-TAVI 1 trial has demonstrated that the Myval and Myval Octacor transcatheter heart valves (Meril Life Sciences) compare favorably with ...